作者:Wolfgang Grell、Rudolf Hurnaus、Gerhart Griss、Robert Sauter、Eckhard Rupprecht、Michael Mark、Peter Luger、Herbert Nar、Helmut Wittneben、Peter Müller
DOI:10.1021/jm9810349
日期:1998.12.1
carboxy group further increased activity and duration of action in the rat. The most active racemic compound, 6al (R4 = isobutyl; R = ethoxy), turned out to be 12 times more active than the sulfonylurea (SU) glibenclamide (1). Activity was found to reside predominantly in the (S)-enantiomers. Compared with the SUs 1 and 2 (glimepiride), the most active enantiomer, (S)-6al (AG-EE 623 ZW; repaglinide;
研究了两个系列的降血糖苯甲酸衍生物(5、6)的构效关系。当2-甲氧基被亚烷基亚氨基残基取代时,系列5由美格替宁(3)产生。用顺式3、5-二甲基哌啶子基(5h)和八亚甲基亚氨基(5l)残基观察到最大活性。当将2-甲氧基,5-氟和α-甲基残基替换为2-哌啶子基,5-氢和较大的α-烷基残基时,具有反向酰胺基功能的meglitinide类似物4产生6系列, 分别。羧基邻位的烷氧基残基进一步增加了大鼠的活性和作用时间。最具活性的外消旋化合物6al(R4 =异丁基; R =乙氧基)的活性比磺酰脲(SU)格列本脲(1)高12倍。发现活性主要存在于(S)-对映异构体中。与SUs 1和2(格列美脲)相比,活性最高的对映异构体(S)-6al(AG-EE 623 ZW;瑞格列奈; ED50 = 10 micro / kg po)活性高25和18倍。瑞格列奈对2型糖尿病患者是一种有用的治疗药物。FDA和EMEA最